USA 111:17661771 Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer
Laboratory Tests During the initial treatment of patients with pernicious anemia, serum potassium must be observed closely the first 48 hours and potassium replaced if necessary
Engagement fatigue: Frequent tracking can become burdensome when users already manage medication and clinical appointments
What users commonly report: This is where most responders describe the first real indicators: 2-4 lbs of fat loss (in a caloric deficit) Slightly looser waistband Subtle reduction in lower abdominal or love handle fullness Better definition in areas that were previously "stubborn" What determines results: Three factors separate responders from non-responders at this stage: Fasted injection injecting on an empty stomach, 30-60 minutes before food